Leila A Kutteh

Author PubWeight™ 41.10^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.	N Engl J Med	2005	33.60
2	Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.	J Clin Oncol	2013	2.15
3	Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.	J Natl Cancer Inst	2011	1.94
4	Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).	Cancer	2007	1.94
5	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.	J Clin Oncol	2011	1.21
6	Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.	Cancer	2013	1.06
7	Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.	Clin Cancer Res	2013	0.82